Department of Medical Biology, Ege University School of Medicine, Izmir, Turkey.
Department of Medical Biology, Ege University School of Medicine, Izmir, Turkey.
Biomed Pharmacother. 2017 Nov;95:1000-1012. doi: 10.1016/j.biopha.2017.08.084. Epub 2017 Sep 12.
Resistance to chemotherapeutics including platinum agents, nucleoside analogues, topoisomerase and microtubule inhibitors is the most important problem in the treatment of many cancer. Several resistance mechanisms has been described for each group and researchers have been trying to develop new approaches to overcome chemoresistance. miRNAs are the regulators of gene transcription at the post-transcriptional level. Dysregulated miRNAs have been reported in cancer tumorigenesis, diagnosis and prognosis and they are promising new therapeutic approaches to improve diagnosis and predictions of outcomes and response to chemotherapy. In this article, we summarized the results from 2015 January to 2017 June which explore the roles of miRNAs in the development of the chemotherapy resistance.
在许多癌症的治疗中,包括铂类药物、核苷类似物、拓扑异构酶和微管抑制剂在内的化疗药物耐药性是最重要的问题。每种药物都有几种耐药机制,研究人员一直在试图开发新的方法来克服化疗耐药性。miRNAs 是转录后水平基因转录的调节因子。在癌症的发生、诊断和预后中已经报道了失调的 miRNAs,它们是改善诊断和预测结果以及对化疗反应的有前途的新治疗方法。在本文中,我们总结了 2015 年 1 月至 2017 年 6 月的研究结果,探讨了 miRNAs 在化疗耐药性发展中的作用。